Listed

Tempest Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2013

Filed with the SEC on Feb 27, 2014 and accepted by EDGAR at Feb 27, 2014, 09:33 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2013-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2013-01-01 to 2013-12-31$15.8mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2013-01-01 to 2013-12-31−$29.1mus-gaap:OperatingIncomeLoss
Income tax12 months2013-01-01 to 2013-12-31$0us-gaap:IncomeTaxExpenseBenefit
Net income12 months2013-01-01 to 2013-12-31−$29.0mus-gaap:NetIncomeLoss
Diluted EPS12 months2013-01-01 to 2013-12-31−$1.80us-gaap:EarningsPerShareBasicAndDiluted
Capital expenditure12 months2013-01-01 to 2013-12-31$719.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2013-12-31$18.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2013-12-31$45.1mus-gaap:AssetsCurrent
Total assetsAt period end2013-12-31$47.5mus-gaap:Assets
Current liabilitiesAt period end2013-12-31$5.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2013-12-31$5.8mus-gaap:Liabilities
Shareholders' equityAt period end2013-12-31$41.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001047469-14-001433. Last ingested by Listed: Nov 15, 2026, 00:20 ET. Listed shows no prices and gives no investment advice.